207 related articles for article (PubMed ID: 16407611)
1. Evolving molecular-based targeted therapy for cancer: an exciting field.
Carneiro B; Hsiao K; Khandekar J
Compr Ther; 2005; 31(4):299-305. PubMed ID: 16407611
[TBL] [Abstract][Full Text] [Related]
2. Targeted strategies in the treatment of metastatic colon cancer.
Reidy D; Saltz L
J Natl Compr Canc Netw; 2007 Oct; 5(9):983-90. PubMed ID: 17977504
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor as a target for anti-cancer agent design.
Cao J; Fang H; Wang B; Ma C; Xu W
Anticancer Agents Med Chem; 2010 Jul; 10(6):491-503. PubMed ID: 20698825
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinases as targets in cancer therapy - successes and failures.
Traxler P
Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
[TBL] [Abstract][Full Text] [Related]
5. Researchers describe findings for targeted cancer therapies.
Stephenson J
JAMA; 2000 Jul; 284(3):293-5. PubMed ID: 10891943
[No Abstract] [Full Text] [Related]
6. Epidermal growth factor receptor pathway inhibitors.
Baselga J; Cortes J
Cancer Chemother Biol Response Modif; 2005; 22():205-23. PubMed ID: 16110613
[No Abstract] [Full Text] [Related]
7. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy.
Ciardiello F; Troiani T; Bianco R; Orditura M; Morgillo F; Martinelli E; Morelli MP; Cascone T; Tortora G
Ann Oncol; 2006 Jun; 17 Suppl 7():vii109-14. PubMed ID: 16760272
[TBL] [Abstract][Full Text] [Related]
8. Functional Inhibition of VEGF and EGFR Suppressors in Cancer Treatment.
Nayarisseri A; Singh SK
Curr Top Med Chem; 2019; 19(3):178-179. PubMed ID: 30950335
[No Abstract] [Full Text] [Related]
9. Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules.
Caraglia M; Santini D; Bronte G; Rizzo S; Sortino G; Rini GB; Di Fede G; Russo A
Curr Drug Metab; 2011 Dec; 12(10):944-55. PubMed ID: 21787268
[TBL] [Abstract][Full Text] [Related]
10. Developmental therapeutics for inflammatory breast cancer: Biology and translational directions.
Costa R; Santa-Maria CA; Rossi G; Carneiro BA; Chae YK; Gradishar WJ; Giles FJ; Cristofanilli M
Oncotarget; 2017 Feb; 8(7):12417-12432. PubMed ID: 27926493
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapies for advanced non-small cell lung cancer.
Starakis I; Nikolakopoulos A; Mazokopakis EE
Comb Chem High Throughput Screen; 2012 Sep; 15(8):641-55. PubMed ID: 22409867
[TBL] [Abstract][Full Text] [Related]
12. Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
Dear R; Wilcken N; Shannon J
Aust Fam Physician; 2008; 37(1-2):45-9. PubMed ID: 18239753
[TBL] [Abstract][Full Text] [Related]
13. Predicting response to EGFR-tyrosine kinase inhibitors among diverse ancestries: just way too polymorphic.
Zbuk KM; Eng C
Cancer Biol Ther; 2007 Jan; 6(1):112-5. PubMed ID: 17264670
[No Abstract] [Full Text] [Related]
14. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A; Rojo F; Rovira A; Albanell J
Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
[No Abstract] [Full Text] [Related]
15. Cetuximab as a single agent or in combination with chemotherapy in lung cancer.
Kim ES
Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S80-4. PubMed ID: 15638964
[TBL] [Abstract][Full Text] [Related]
16. [Targeted therapies. New hopes, new challenges].
Barlési F
Rev Mal Respir; 2008 Jun; 25(6):661-2. PubMed ID: 18772823
[No Abstract] [Full Text] [Related]
17. A review of EGFR targeted therapy.
Baselga J
Clin Adv Hematol Oncol; 2003 Apr; 1(4):218-9. PubMed ID: 16224409
[No Abstract] [Full Text] [Related]
18. Monoclonal antibodies in the treatment of advanced colorectal cancer.
Capdevila J; Saura C; Macarulla T; Casado E; Ramos FJ; Tabernero J
Eur J Surg Oncol; 2007 Dec; 33 Suppl 2():S24-34. PubMed ID: 17981431
[TBL] [Abstract][Full Text] [Related]
19. Directed therapies in lung cancer: new hope?
Parente Lamelas I; Abal Arca J; Fírvida Pérez JL
Arch Bronconeumol; 2012 Oct; 48(10):367-71. PubMed ID: 22551924
[TBL] [Abstract][Full Text] [Related]
20. Anti-Angiogenics: Current Situation and Future Perspectives.
Zirlik K; Duyster J
Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
